Transfusion Medicine Reviews
Volume 22, Issue 2 , Pages 103-116 , April 2008

The Mechanisms of Action of Intravenous Immunoglobulin and Polyclonal Anti-D Immunoglobulin in the Amelioration of Immune Thrombocytopenic Purpura: What Do We Really Know?

  • Andrew R. Crow
    • ,
  • Alan H. Lazarus

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Alan H. Lazarus, PhD, Associate Professor of Medicine, St Michael's Hospital, Rm 2-001 Shuter Wing, 30 Bond St, Toronto, Ontario, Canada M5B 1W8.

References 

  1. Nieswandt B, Bergmeier W, Rackebrandt K, et al. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96:2520–2527
  2. Olsson B, Andersson PO, Jernas M, et al. T-cell–mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9:1123–1124
  3. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood. 2006;108:943–946
  4. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–1231
  5. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484–486
  6. Siragam V, Brinc D, Crow AR, et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?. J Clin Invest. 2005;115:155–160
  7. Siragam V, Crow AR, Brinc D, et al. Intravenous immunoglobulin ameliorates ITP via activating Fcgamma receptors on dendritic cells. Nat Med. 2006;12:688–692
  8. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983;2:193–195
  9. Salama A, Kiefel V, Amberg R, et al. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)]. Blut. 1984;49:29–35
  10. Becker T, Kuenzlen E, Salama A, et al. Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D). Eur J Pediatr. 1986;145:166–169
  11. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344:703–707
  12. Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood. 1997;89:2689–2700
  13. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: Studies in experimental immune thrombocytopenia. Blood. 2001;98:1095–1099
  14. Cooper N, Heddle NM, Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: Modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol. 2004;124:511–518
  15. Song S, Crow AR, Siragam V, et al. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood. 2005;105:1546–1548
  16. Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med. 1986;314:1236–1239
  17. Ericson SG, Coleman KD, Wardwell K, et al. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br J Haematol. 1996;92:718–724
  18. Flesch BK, Achtert G, Neppert J. Inhibition of monocyte and polymorphonuclear granulocyte immune phagocytosis by monoclonal antibodies specific for Fc gamma RI, II and III. Ann Hematol. 1997;74:15–22
  19. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. 1982;306:1254–1258
  20. Bussel JB, Kimberly RP, Inman RD, et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood. 1983;62:480–486
  21. Uchida T, Yui T, Umezu H, et al. Prolongation of platelet survival in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. Thromb Haemost. 1984;51:65–66
  22. Macintyre EA, Linch DC, Macey MG, et al. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br J Haematol. 1985;60:387–388
  23. Newland AC, Macey MG. Immune thrombocytopenia and Fc receptor–mediated phagocyte function. Ann Hematol. 1994;69:61–67
  24. Crow AR, Song S, Semple JW, et al. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol. 2001;115:679–686
  25. Crow AR, Lazarus AH. Role of Fcg receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25:S14–S18
  26. Nimmerjahn F, Ravetch JV. Fcgamma receptors: Old friends and new family members. Immunity. 2006;24:19–28
  27. Hirano M, Davis RS, Fine WD, et al. IgEb immune complexes activate macrophages through FcgammaRIV binding. Nat Immunol. 2007;8:762–771
  28. Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti–Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest. 1986;77:2010–2018
  29. Song S, Crow AR, Freedman J, et al. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: An alternative to IVIG. Blood. 2003;101:3708–3713
  30. van Mirre E, Teeling JL, van der Meer JW, et al. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb. J Immunol. 2004;173:332–339
  31. Lamoureux J, Aubin E, Lemieux R. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: A role in the in vivo mechanisms of action of IVIg?. Int Immunol. 2004;16:929–936
  32. Soubrane C, Tourani JM, Andrieu JM, et al. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood. 1993;81:15–19
  33. Bussel J, Patel V, Dunbar C, et al. GMA161 treatment of refractory ITP: efficacy of Fc{gamma}-RIII blockade. Blood. 2006;108:1074;[abst]
  34. Burdach SE, Evers KG, Geursen RG. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous immunoglobulin G: Comparative efficacy of 7S and 5S preparations. J Pediatr. 1986;109:770–775
  35. Tovo PA, Miniero R, Fiandino G, et al. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J Pediatr. 1984;105:676–677
  36. Crow AR, Song S, Freedman J, et al. IVIg-mediated amelioration of murine ITP via Fc{gamma}RIIB is independent of SHIP1, SHP-1, and Btk activity. Blood. 2003;102:558–560
  37. Crow AR, Song S, Siragam V, et al. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer. 2006;47:710–713
  38. Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol. 2006;135:97–100
  39. Lin SY, Kinet JP. Immunology. Giving inhibitory receptors a boost. Science. 2001;291:445–446
  40. Ott VL, Fong DC, Cambier JC. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001;108:S95–S98
  41. Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: An insight into the immunoregulatory mechanisms. Int Immunopharmacol. 2006;6:528–534
  42. Berchtold P, Dale GL, Tani P, et al. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood. 1989;74:2414–2417
  43. Barbano G, Saleh MN, Mori PG, et al. Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia. Blood. 1989;73:662–665
  44. Debre M, Bonnet MC, Fridman WH, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993;342:945–949
  45. Marchalonis JJ, Kaymaz H, Dedeoglu F, et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci U S A. 1992;89:3325–3329
  46. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin IVIg). Ther Immunol. 1994;1:269–277
  47. Vassilev T, Gelin C, Kaveri SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins IVIg). Clin Exp Immunol. 1993;92:369–372
  48. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 2004;101:14210–14215
  49. Bendtzen K, Hansen MB, Ross C, et al. High-avidity autoantibodies to cytokines. Immunol Today. 1998;19:209–211
  50. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell–mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest. 1996;97:865–869
  51. Delfraissy JF, Tchernia G, Laurian Y, et al. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1985;60:315–322
  52. Dammacco F, Iodice G, Campobasso N. Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: Effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br J Haematol. 1986;62:125–135
  53. Macey MG, Newland AC. CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Haematol. 1990;76:513–520
  54. Tsubakio T, Kurata Y, Katagiri S, et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol. 1983;53:697–702
  55. Chiller JM, Habicht GS, Weigle WO. Cellular sites of immunologic unresponsiveness. Proc Natl Acad Sci U S A. 1970;65:551–556
  56. Sundblad A, Huetz F, Portnoi D, et al. Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice. J Autoimmun. 1991;4:325–339
  57. Sundblad A, Marcos M, Huetz F, et al. Normal serum immunoglobulins influence the numbers of bone marrow pre-B and B cells. Eur J Immunol. 1991;21:1155–1161
  58. Kekow J, Reinhold D, Pap T, et al. Intravenous immunoglobulins and transforming growth factor beta. Lancet. 1998;351:184–185
  59. Altznauer F, von Gunten S, Spath P, et al. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol. 2003;112:1185–1190
  60. Vuist WM, Van Schaik IN, Van Lint M, et al. The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol. 1997;17:301–310
  61. Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998;161:3781–3790
  62. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490–493
  63. Zhou B, Zhao H, Yang RC, et al. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol. 2005;54:107–116
  64. Sewell WA, North ME, Cambronero R, et al. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol. 1999;116:509–515
  65. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994;84:2136–2143
  66. Arend WP, Leung DY. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev. 1994;139:71–78
  67. Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol. 1998;16:27–55
  68. Iizasa H, Yoneyama H, Mukaida N, et al. Exacerbation of granuloma formation in IL-1 receptor antagonist–deficient mice with impaired dendritic cell maturation associated with Th2 cytokine production. J Immunol. 2005;174:3273–3280
  69. Bruhns P, Samuelsson A, Pollard JW, et al. Colony-stimulating factor-1–dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 2003;18:573–581
  70. Crow AR, Song S, Semple JW, et al. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?. Blood. 2007;109:155–158
  71. Aubin E, Lemieux R, Bazin R. Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti–red blood cell antibodies in a mouse model of immune thrombocytopenic purpura. Br J Haematol. 2007;136:837–843
  72. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood. 1991;77:376–380
  73. Lutz HU, Stammler P, Bianchi V, et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood. 2004;103:465–472
  74. Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins. Nat Med. 2003;9:431–438
  75. Basta M, Langlois PF, Marques M, et al. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood. 1989;74:326–333
  76. Mollnes TE, Hogasen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol. 1998;48:312–317
  77. Hed J. Role of complement in immune or idiopathic thrombocytopenic purpura. Acta Paediatr Suppl. 1998;424:37–40
  78. Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature. 1989;337:184–187
  79. Fateh-Moghadam A, Wick M, Besinger U, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;1:848–849
  80. Hammarstrom L, Abedi MR, Hassan MS, et al. The SCID mouse as a model for autoimmunity. J Autoimmun. 1993;6:667–674
  81. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–1876
  82. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 2002;100:2087–2093
  83. Israel EJ, Wilsker DF, Hayes KC, et al. Increased clearance of IgG in mice that lack beta 2–microglobulin: Possible protective role of FcRn. Immunology. 1996;89:573–578
  84. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin–containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93:5512–5516
  85. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost. 2002;88:898–899
  86. Akilesh S, Petkova S, Sproule TJ, et al. The MHC class I–like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. 2004;113:1328–1333
  87. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115:3440–3450
  88. Banchereau J, Schuler-Thurner B, Palucka AK, et al. Dendritic cells as vectors for therapy. Cell. 2001;106:271–274
  89. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758–765
  90. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670–673
  91. Jefferis R, Lund J. Interaction sites on human IgG-Fc for FcgammaR: Current models. Immunol Lett. 2002;82:57–65
  92. Tha-In T, Metselaar HJ, Tilanus HW, et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bi-directional interaction between dendritic cells and natural killer cells. Blood. 2007;110:3253–3262
  93. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology. 1990;71:372–376
  94. Ling ZD, Ziltener HJ, Webb BT, et al. Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. Cell Immunol. 1990;129:95–103
  95. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol. 1989;143:4104–4109
  96. Zhuang Q, Mazer B. Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin. J Allergy Clin Immunol. 2001;108:229–234
  97. Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007;26:67–78
  98. Andrew M, Blanchette VS, Adams M, et al. A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr. 1992;120:522–527
  99. Salama A, Kiefel V, Mueller-Eckhardt C. Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol. 1986;22:241–250
  100. Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991;77:1884–1893
  101. Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol. 1998;35:14–22
  102. Ambriz-Fernandez R, Martinez-Murillo C, Quintana-Gonzalez S, et al. Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG. Arch Med Res. 2002;33:536–540
  103. Bussel JB, Graziano JN, Kimberly RP. Anti-D Ig for treatment of immune thrombocytopenic purpura (letter). Blood. 1991;2157–2158
  104. Oksenhendler E, Bierling P, Brossard Y, et al. Anti-RH immunoglobulin therapy for human immunodeficiency virus–related immune thrombocytopenic purpura. Blood. 1988;71:1499–1502
  105. Ramadan KM, El-Agnaf M. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. Clin Lab Haematol. 2005;27:267–269
  106. Bussel JB, Kaufmann CP, Ware RE, et al. Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?. Am J Hematol. 2001;67:27–33
  107. Boughton BJ, Cooke RM, Smith NA, et al. Autoimmune thrombocytopenia: anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment. Autoimmunity. 1994;18:141–144
  108. Branch DR, Shabani F, Lund N, et al. Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-beta and prostaglandin E2. Transfusion. 2006;46:1316–1322
  109. Semple JW, Allen D, Rutherford M, et al. Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. Am J Hematol. 2002;69:225–227
  110. Malinowska I, Obitko-Pludowska A, Buescher ES, et al. Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J. 2001;2:242–249
  111. Coopamah MD, Freedman J, Semple JW. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood. 2003;102:2862–2867
  112. Deng R, Balthasar JP. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood. 2007;109:2470–2476
  113. Meyer O, Kiesewetter H, Hermsen M, et al. Efficacy and safety of anti-D given by subcutaneous injection to patients with autoimmune thrombocytopenia. Eur J Haematol. 2004;73:71–72
  114. Borgna-Pignatti C, Battisti L, Zecca M, et al. Treatment of chronic childhood immune thrombocytopenic purpura with intramuscular anti-D immunoglobulins. Br J Haematol. 1994;88:618–620
  115. Urbaniak SJ. Alloimmunity to RhD in humans. Transfus Clin Biol. 2006;13:19–22

 This work was supported by the Canadian Institutes of Health Research, Ottawa, Ontario.

PII: S0887-7963(07)00110-1

doi: 10.1016/j.tmrv.2007.12.001

Transfusion Medicine Reviews
Volume 22, Issue 2 , Pages 103-116 , April 2008

Article Tools

* Image Usage & Resolution